COMPASS Pathways 2026: Revenue ($10.01M), EPS ($0.31) — 10-Q Summary

What happened

COMPASS Pathways reported a net loss of $9.83 million for 2026, compared with a $137.72 million loss in 2025. It also reported comprehensive losses of $10.01 million and diluted loss per share of $0.31.

Confirmed

Global impact / market context

The much smaller loss means the company spent far less cash than the year before, which extends how long it can fund operations. Progress on depression and PTSD treatments could matter more to investors than the reported loss figures.

Analyst inference

This is a drug developer with no approved product yet, so it depends on outside funding until launch. Positive trial results and an ongoing FDA review are the main drivers, while approval timing and launch spending shape how much cash the company needs.

Analyst inference

What to watch

1. The FDA's rolling review of the treatment-resistant depression application is ongoing, and COMP360 received a National Priority Voucher in April 2026, which may speed review. Confirmed
2. The FDA accepted COMP360's investigational application for PTSD, enabling a Phase 2b/3 trial; the company plans enrollment and study advancement, so watch for updates. Proposed
3. The company is expanding staffing in market access, reimbursement, supply chain and launch preparation ahead of possible approval, so watch whether these costs increase future losses. Analyst inference

Evidence

• Original source link unavailable